Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

The Court for the Central District of California has sided with Axonics finding the company did not breach Medtronic’s ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy ...

Axonics, Inc. (AXNX) comes out victorious in a patent trial against Medtronic (MDT), as the jury rules in its favor, awarding ...

A jury unanimously found that Axonics did not infringe any of the three patents-in-suit brought against the company by Medtronic in a patent infringement lawsuit in the U.S. District Court for the ...

Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the ...

Medtronic's MiniMed 670G - the closest thing yet to an artificial pancreas - has been launched in the US. The so-called 'hybrid closed-loop' system comprises a blood glucose sensor ...

Advanced materials are key to next-gen sensors, improving sensitivity and durability for critical applications in healthcare ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Medtronic delivered a strong first-quarter earnings report. The company benefits from continued market adoption of several new product launches over the past year. The stock looks attractive ...